In a phase 1/2 study, 124I-evuzamitide PET/CT demonstrated high sensitivity (≈93.6%) for detecting cardiac amyloid, with uptake observed in both ATTR and AL amyloidosis. Here, TTR is linked to AL amyloidosis.